Sign up for access to exclusive content, events, materials and updates from OWL.
Rarely will you find a value as great as an OWL membership! By becoming a member you establish yourself as committed to "Advancing Diversity in Leadership" and in standing as a leader for today's world. You'll also be affiliated with the best and brightest in Ophthalmology. Take a look here at some of our Champion members!
LEARN MOREIt’s time to honor your peers who are advancing diversity in leadership.OWL is pleased to accept nominations for the 2022…
On June 21, 2022, OWL and Alcon collaborated to host our second annual virtual program “Eyes on Inclusion: Transitioning to…
Make Your Voice Heard! Participate in our Ophthalmic Business and Leadership Trends Survey for 2022! This 5-minute survey will help…
Developing leaders is OWL's mission and our specialty! Get terrific experience and benefit from the best-of-the-best networking in Ophthalmology when you get involved in OWL:
OWL is a 501(c)3 organization, meaning any financial contribution is 100% tax-deductible. OWL focuses the investment of members’ dues on programs and events that will benefit members (our admin costs are low compared to other nonprofits).
Your company can align with OWL's mission by having a presence at our events and benefit from exposure on our social mediachannels and in our member communications. Organizations and companies that want to be involved at the highest level can enroll their associates as virtual members, receive educational programs and get sponsorship exposure by becoming an OWL Partner.
LEARN MOREThe OWL Awards are given annually at OWL's Signature Event during AAO. The finalists are distinguished and respected - always an impressive group!
Nominations for the OWL Awards open in the Summer. A Nominations Committee selects the finalists and then OWL members cast their votes in the Fall.
Contact Us for information on nominating a colleague as a ‘Rising Star’, ‘Catalyst’ or ‘Visionary’ in Ophthalmology.
LEARN MORE
President and Founder of Ocuphire Pharma
Mina Sooch is CEO, President, and Founder of Ocuphire Pharma and Vice-Chair of the Board. With over 25 years of pharmaceutical and biotech experience as CEO, entrepreneur, venture capitalist, and strategist, Mina has successfully raised hundreds of millions of dollars for over 10 biotechnology, pharmaceutical, and drug/device companies, which included leading three successful public Nasdaq listings, including 2 IPOs (Gemphire and ProNAi) and taking Ocuphire public in late 2020 (Nasdaq:OCUP). She was a co-founder and CEO of Gemphire Therapeutics, a publicly-traded, clinical-stage cardiovascular company as well as co-founder and CEO of ProNAi Therapeutics, a public, clinical-stage DNAi oncology company. Mina also co-founded in 2003 Apjohn Ventures Fund with a focus on early-stage life sciences companies based in Michigan. Earlier in her career, from 1993-2000, she served as a global account manager at Monitor Group, a top-tier global strategy consulting firm based in Boston specializing in healthcare, M&A, and corporate finance. Mina currently serves on the board of Priority Health (2nd largest healthcare plan in Michigan). She has served on the boards of over 12 private, public, and nonprofit firms, and has been the recipient of numerous awards, including being named one of the Deal Makers of the year in 2016 by Crain’s Detroit Business and E&Y Entrepreneur of the Year 2021 Regional Finalist. Mina received an M.B.A. from Harvard Business School and a B.S. summa cum laude in Chemical Engineering from Wayne State University in Detroit, Michigan.
More OWL ChampionsPresident of Carl Zeiss Meditec USA
Andrew I. Chang is President of Carl Zeiss Meditec USA, Inc., Head of Global Sales Ophthalmic Devices, Board Member for MicroOptx, ASCRS Foundation, Ophthalmology Foundation, Cataract Technologies Inc. and founding member of Vanguard Ophthalmology Society.
Andy’s breadth of experience across the ophthalmic industry in diagnostic and surgical devices, as well as pharmaceuticals has made him an exceptional leader in the industry. His understanding of the needs of the clinician and how technology can improve their work has successfully transitioned some of the ophthalmic industry’s most influential companies to the next level in market leadership. Through partnership with doctors from early-stage development to integrating and implementing cuttingedge technologies into daily clinical practice Andy has made significant contributions to the expansion of offerings for ophthalmic and optometric customers worldwide.
Prior to joining ZEISS, Andy was General Manager and Senior Vice President for Bausch + Lomb Surgical where he led the sales, marketing, operations and business development for the US. Previously at Optimedica Corporation / Abbott Medical Optics, Inc., Andy led the marketing and launch of new laser systems and new indications globally. At ISTA Pharmaceutical / Bausch + Lomb, Andy held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals.
More OWL Champions